首位患者参加了Obefazimod对克罗恩病的第二期b ENHANCE- CD试验. 1st patient enrolled in Phase 2b ENHANCE-CD trial testing obefazimod for Crohn's disease.

一家生物技术公司Abivax已经将其第一名患者纳入了第2b期ENHANCE- CD试验,试验了Obefazimod对克罗恩病的治疗. Abivax, a biotechnology firm, has enrolled its first patient in the Phase 2b ENHANCE-CD trial, testing obefazimod for Crohn's disease. 这项研究将评估该药物在未接受其他治疗的中度至重度疾病的成年人中的效力和安全性。 This study will assess the drug's efficacy and safety in adults with moderate to severe disease who haven't responded to other treatments. 该试验包括12周的启动阶段,40周的维持阶段和48周的延长阶段. The trial includes a 12-week induction, a 40-week maintenance, and a 48-week extension phase. 在治疗性结肠炎的第三期试验中,Abivax也在推进obefazimod的研究. Abivax is also advancing obefazimod in Phase 3 trials for ulcerative colitis.